Summary
The provided claims are about pricing/cost/coverage and do not appear in the supplied FDA label excerpts; therefore they are not label-supported, and the response also omits key label items relevant to safety (contraindication and required lung-function assessment) when making safety-adjacent statements.
Category Scores
Accurate Statements
Afrezza is an inhaled insulin product.
Supported that AFREZZA is an inhaled product is implicitly consistent with the label excerpts referring to “AFREZZA dosing” and spirometry prior to initiation; however the supplied excerpts do not explicitly state the phrase “inhaled insulin product.”
Unsupported Statements
Afrezza pricing varies based on the pharmacy, insurance coverage, and whether patients pay cash or use a copay program.
No pricing/cost/coverage information is present in the supplied label sections.
Publicly available price figures for Afrezza are often presented as list price.
No pricing/list price discussion is present in the supplied label sections.
The amount patients actually pay for Afrezza can be much lower with coverage.
No out-of-pocket/cost outcomes are present in the supplied label sections.
Out-of-pocket cost for Afrezza depends on whether patients have commercial insurance or Medicare coverage.
No payer-type/out-of-pocket/cost discussion is present in the supplied label sections.
Out-of-pocket cost for Afrezza depends on the plan’s formulary tier and prior authorization requirements.
No formulary tier/prior authorization or cost discussion is present in the supplied label sections.
Out-of-pocket cost for Afrezza depends on deductible status.
No deductible/out-of-pocket cost discussion is present in the supplied label sections.
Out-of-pocket cost for Afrezza depends on whether patients can use a manufacturer or pharmacy discount program.
No discount-program discussion is present in the supplied label sections.
Two patients with the same insurance type can see different copays for Afrezza because inhaled insulin products can be treated differently by insurers.
No insurer-copay variation or treatment-differences discussion is present in the supplied label sections.
“Generic” availability for Afrezza depends on whether and when lower-cost equivalents enter the market.
No discussion of generic availability or market entry is present in the supplied label sections.
Many insulin products remain under strong brand protection for years.
No patent/brand protection duration discussion is present in the supplied label sections.
Cash prices for Afrezza may stay high until competing products are allowed and widely adopted.
No pricing/market adoption discussion is present in the supplied label sections.
Insurer coverage can sharply lower the amount patients pay even if a drug’s list price is high.
No pricing/out-of-pocket/coverage impact discussion is present in the supplied label sections.
Many insurance plans require prior authorization for insulin formulations based on previous trials of other insulins.
No payer prior authorization requirements are present in the supplied label sections.
Many insurance plans require prior authorization for insulin formulations based on clinical criteria for inhaled insulin use.
No payer prior authorization requirements are present in the supplied label sections.
Many insurance plans require prior authorization for insulin formulations based on documentation of why Afrezza is necessary.
No payer prior authorization/documentation requirements are present in the supplied label sections.
A patient’s final bill for Afrezza often depends more on the insurer’s formulary and coverage policy than on list price.
No billing/cost dependence or formulary policy discussion is present in the supplied label sections.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Key safety-relevant labeling is not addressed in the provided claims set: AFREZZA is contraindicated in chronic lung disease (asthma/COPD) due to risk of acute bronchospasm and requires lung assessment (medical history/physical exam/spirometry FEV1) prior to initiation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are primarily about pricing/coverage rather than prescribing or safety; however, the response does not include label-required contraindication and pre-initiation lung-function assessment messaging, which is important for safe use. No direct contradictions to the supplied safety label excerpts were identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Most claims are about pricing/insurance mechanics and are not supported by the supplied FDA labeling excerpts.
Suggested Improvement
Limit statements to label-supported content from the provided sections (contraindication in chronic lung disease, pre-initiation lung assessment, and risk of acute bronchospasm) and remove or separately source non-label pricing/coverage assertions.